Prostate cancer

Researchers are testing a combination of two radiation techniques for men with intermediate or high risk prostate cancer. Participants receive a shortened course of external beam radiation followed by a single high-dose brachytherapy boost, with optional hormone therapy. The tria…

Researchers in Denmark are testing a targeted radiation technique called focal brachytherapy for men with early prostate cancer. The treatment places radioactive sources directly into the tumor, guided by MRI and ultrasound, to destroy cancer while leaving the rest of the prostat…

Researchers are testing a robotic approach to remove the prostate through the perineum, the area between the scrotum and anus, in men with localized prostate cancer. The study aims to see if the procedure can be completed safely and effectively using the GelPOINT device and a rob…

This phase 3 trial tests whether a shorter course of higher-dose radiation can match or improve upon standard pelvic radiation plus a brachytherapy boost for men with high-risk prostate cancer. Participants also receive hormone therapy for 28 months. The study compares side effec…

This early-phase study tests a personalized vaccine made from a patient's own immune cells and tumor markers. It aims to help the immune system attack advanced prostate cancer that has stopped responding to standard treatments. About 9 to 18 men will receive four doses over eight…

This early-stage study tests a personalized vaccine (PGV001) combined with an immune booster (CDX-301) in 27 men who have had aggressive prostate cancer but currently show no signs of tumor. The goal is to see if the vaccine is safe and can train the immune system to recognize an…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This phase 2 study tests pembrolizumab (Keytruda) in 40 men with metastatic castration-resistant prostate cancer that has specific genetic flaws (mismatch repair deficiency or CDK12 inactivation). The goal is to see if the drug can shrink tumors or slow the cancer. Researchers wi…

This study tests a combination of three drugs—radium-223, M3814, and avelumab—in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bone. The goal is to see if the combination can slow cancer growth better than radium-223 alone. The…

This early-stage study tests a new drug called JSB462 (Luxdegalutamide) in 15 Japanese men whose prostate cancer has spread to other parts of the body. The main goal is to check the drug's safety and how the body processes it. Participants take the drug once daily with food.

This Phase II trial tests a new drug, JSB462 (luxdegalutamide), combined with a radioactive therapy (Pluvicto) in 138 men with PSMA-positive metastatic castration-resistant prostate cancer that has progressed after prior treatments. The study aims to see if the combination works …

This study tests whether a precise, short-course radiation method (SBRT) works as well as a slightly longer radiation approach (hypofractionated radiotherapy) for men whose prostate cancer has come back or spread to a few spots after surgery. About 118 participants will receive o…

This study tests whether a shorter, more intense radiation treatment (5 sessions) is better than the standard 20-session approach for men with intermediate- or high-risk prostate cancer that hasn't spread. The goal is to improve cancer control while keeping side effects low. Abou…

Researchers are testing a new drug called FOR46, which seeks out a protein called CD46 on cancer cells, together with enzalutamide, a standard hormone therapy, in men whose prostate cancer has spread and worsened despite prior treatment with abiraterone. The trial aims to find th…

This study tests a procedure called TULSA that uses MRI images to guide high-energy ultrasound waves to destroy prostate cancer tumors. About 21 adults with early-stage prostate cancer that shows up on MRI will receive this heat-based treatment. The goal is to see if the approach…

This study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in people with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combination can lowe…

This study tests whether adding the immune-boosting drug Sipuleucel-T (Provenge) to standard hormone therapy can help men with advanced prostate cancer that is no longer responding to hormones alone. The trial involves 26 participants who will receive either Sipuleucel-T alone or…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This study tests whether a one-time procedure called brachytherapy, where tiny radioactive seeds are placed directly into the prostate, can control intermediate risk prostate cancer without needing additional treatments. Three hundred men with specific tumor features (Gleason sco…

This phase 3 trial is testing whether adding the drug niraparib to standard therapy (abiraterone and prednisone) can slow cancer growth in men with metastatic castration-sensitive prostate cancer who have specific inherited or tumor gene mutations. About 700 participants are bein…

This study tests different combinations of approved drugs in 196 men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see which combinations work best to extend life and control the cancer. Participants receive standard hormo…

Men with prostate cancer often receive androgen deprivation therapy, which can raise the risk of heart problems and metabolic issues. This trial tests whether adding semaglutide, a GLP-1 receptor agonist, can control cardiovascular risk factors like weight, blood pressure, and ch…

This study tests a gel called SpaceIT that is placed between the prostate and rectum before radiation therapy for prostate cancer. The gel acts as a spacer to reduce radiation reaching the rectum, potentially lowering side effects. About 230 adults with low- to intermediate-risk …

This study looks at the long-term safety of the drug enzalutamide in people with prostate cancer who have already been taking it in a previous study and are still benefiting. About 900 participants will continue their current treatment and be monitored for side effects. The goal …

This phase 3 trial tests a radioactive drug called 177Lu-PSMA-617 in 469 men with advanced prostate cancer that has stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. Researchers compare it to switching to another hormone th…

This study tests a radioactive drug (lutetium-177) alone or combined with newer hormone therapy in 49 men with a specific type of prostate cancer that has stopped responding to standard hormone therapy but hasn't spread on regular scans. The goal is to see if the treatment can lo…

This study tests a new radioactive drug, 225Ac-PSMA-R2, in men with advanced prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to seek out and destroy cancer cells that have a specific marker called PSMA. The trial will check…

This study tests whether a new drug (BMS986365) combined with hormone therapy (degarelix) can safely shrink or eliminate high-risk prostate cancer before standard surgery. About 30 participants will receive the combination for several months, then have their prostate removed. The…

This early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…

This study tests whether adding capivasertib to standard hormone therapy (abiraterone plus prednisone and ADT) can slow cancer growth better than standard therapy alone. It includes about 1,000 men with newly diagnosed, hormone-sensitive prostate cancer that has spread and has a …

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This study looks at whether a special gene test can help men with low-risk prostate cancer decide to monitor their cancer instead of treating it right away. About 805 men with early-stage prostate cancer will be randomly assigned to have the gene test or not. The goal is to see i…

This phase 2 trial tests a multi-drug approach for men with aggressive variant prostate cancer that has spread. First, patients receive chemotherapy (cabazitaxel and carboplatin) plus an immunotherapy (cetrelimab). Then, they are randomly assigned to take either a PARP inhibitor …

This study tests a combination of two drugs—olaparib and radium-223—in men with castration-resistant prostate cancer that has spread to bone. Olaparib blocks a protein that helps cancer cells repair themselves, while radium-223 delivers radiation directly to bone tumors. The tria…

This phase 3 trial compares a new drug, BMS-986365, against standard treatments (docetaxel or other hormone therapies) in 960 men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The main goal is to see if the new drug delays ca…

This study is testing a new drug called xaluritamig in men whose prostate cancer has returned after initial treatment but has not spread. The main goal is to see if the drug is safe and tolerable. About 50 participants will receive the drug, and researchers will monitor side effe…

This phase 3 trial is testing whether a new type of targeted radiation therapy, called 177Lu-PSMA-I&T, can slow the progression of metastatic castration-resistant prostate cancer better than standard hormone therapy. The study enrolls men with prostate cancer that has spread and …

This Phase 3 trial tests whether adding talazoparib (a targeted drug) to standard hormone therapy (enzalutamide) works better than hormone therapy alone for men with metastatic prostate cancer that has a specific DNA repair mutation. About 600 men are participating. The study mea…

This phase II trial tests whether green tea catechins (GTC) can prevent low-risk prostate cancer from progressing in men on active surveillance. 360 participants will receive either GTC or a placebo daily. The study measures changes in a tumor growth marker (Ki-67) in biopsy samp…

This trial tests whether giving a lower dose of radiation in just two sessions can reduce urinary side effects for men with intermediate-risk prostate cancer. All participants receive radiation on an MR-Linac, a machine that combines MRI imaging with radiotherapy for precise targ…

This study tests a new treatment called AB-3028, which uses a patient's own immune cells (T cells) that have been modified in a lab to better attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a type that has stopped responding to ho…

This phase II study tests whether giving an extra-high radiation dose directly to the main prostate tumor, while treating the rest of the prostate with standard SBRT, can reduce the chance of cancer coming back. About 91 men with intermediate-risk prostate cancer will receive fiv…

This trial tests whether high-dose radiation aimed at a few cancer spots can slow the disease in men with prostate cancer that has stopped responding to hormone therapy. Half the participants receive radiation to their metastases, while the other half are watched without immediat…

This study looks at whether men whose metastatic prostate cancer has responded very well to hormone therapy can safely pause treatment. About 79 men will stop their medications under doctor guidance to see if their testosterone levels recover and they remain cancer-free for at le…

This trial tests whether adding metformin, a common diabetes drug, to standard hormone therapy can delay cancer progression in men with newly diagnosed metastatic hormone-sensitive prostate cancer. Half the participants receive metformin alongside androgen deprivation therapy (AD…

This study tests a special scaffold placed during prostate removal surgery to help men regain bladder control. About 266 men will be randomly assigned to get the scaffold or standard care. The goal is to see if the scaffold reduces urine leakage and improves quality of life over …

This study tested a drug called apalutamide in over 1,200 men with a type of prostate cancer that has stopped responding to hormone therapy but has not yet spread. The goal was to see if the drug could delay the cancer from spreading to bones or other organs. Participants took ei…

This phase 3 trial tests whether adding apalutamide to standard treatment (abiraterone and prednisone) can delay cancer growth in men with advanced prostate cancer that no longer responds to hormone therapy. About 982 participants who have not had chemotherapy are randomly assign…

This phase 3 trial tests whether adding apalutamide (a daily pill) to standard hormone therapy helps men with metastatic hormone-sensitive prostate cancer live longer and delay disease progression. Over 1,000 participants received either apalutamide plus hormone therapy or a plac…

This study is for men whose prostate cancer has returned after prostate removal surgery, shown by a rising PSA. It compares standard radiation therapy alone versus radiation plus a drug called apalutamide, which blocks male hormones that fuel cancer growth. The goal is to see if …

This early-stage trial tests a new drug called ARX517, which is designed to find and kill prostate cancer cells while sparing healthy ones. It is being tested alone or with other standard treatments in 183 men with prostate cancer that has spread to other parts of the body. The m…

This study looks at how the body absorbs different versions of two prostate cancer drugs, niraparib and abiraterone acetate, taken together with prednisone. It involves 136 men with metastatic castration-resistant prostate cancer. The goal is to compare the absorption of various …

This phase 3 study tests whether adding the drug apalutamide to standard radiotherapy and hormone therapy can delay cancer spread or death in 692 men with high-risk prostate cancer. Participants are randomly assigned to receive either the standard treatment alone or with apalutam…

This study tests whether adding apalutamide to standard hormone therapy before and after prostate removal surgery can improve outcomes for men with high-risk prostate cancer. About 2,500 participants will receive either the drug combination or a placebo. The goal is to see if the…

This early-stage study tests the drug apalutamide in 19 Chinese men whose prostate cancer has spread and no longer responds to hormone therapy. Researchers want to see how the drug behaves in the body and if it is safe. They will also check if it lowers PSA levels, a marker of ca…

This early-phase trial tests a radioactive drug called tin-117m-DTPA in 24 people with prostate, breast, or lung cancer that has spread to the bones. The drug is designed to deliver low-level radiation directly to bone tumors while being gentler on the bone marrow. Researchers wi…

This study tests a new drug called JNJ-56021927 combined with abiraterone acetate (Zytiga) and prednisone in 57 men with metastatic castration-resistant prostate cancer. The goal is to see how these drugs interact, check safety, and get an early look at effectiveness. All partici…

This phase 3 trial tests whether adding apalutamide (a hormone-blocking drug) to standard hormone therapy and radiation can delay the spread of prostate cancer in high-risk patients. About 1,500 men with localized or locally advanced prostate cancer are participating. The main go…

This early-phase study tests a new drug, JNJ-69086420, that delivers a radioactive particle directly to prostate cancer cells. The trial involves about 144 men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The main goals ar…

This early study tests the safety of TheraSphere PCa, tiny radioactive glass beads injected into the prostate to treat localized prostate cancer. The trial involves 36 men with favorable intermediate-risk cancer and aims to find the maximum safe radiation dose. Researchers will m…

This study tests a new drug called AZD5305 combined with standard hormone therapies in 174 men with metastatic prostate cancer. The goal is to see if the combination is safe and can help control the disease. Participants take daily pills, and researchers monitor side effects and …

This phase 2 trial tests whether adding a second DNA vaccine to a standard immunotherapy (pembrolizumab) can improve outcomes for men with castration-resistant metastatic prostate cancer. About 60 participants will receive either one or two DNA vaccines along with pembrolizumab f…

This trial tests whether stereotactic body radiotherapy (SBRT) using the TrueBeam system can effectively treat localized prostate cancer. The approach delivers high-dose radiation precisely to the tumor, aiming to minimize damage to surrounding healthy tissue. Researchers will tr…

This trial is testing whether giving an experimental drug called enoblituzumab before prostate removal surgery can help fight prostate cancer. Men with intermediate- or high-risk localized prostate cancer will receive the drug weekly for six weeks before their scheduled surgery. …

This study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works. About 362 participants will take part to find the best…

This study tests a radioactive drug called 225Ac-J591 in men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The first part finds a safe dose and schedule, and the second part checks if the drug lowers PSA levels by more than half. About 6…

This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…

This study tests an experimental drug called ARV-766, taken as a pill, in men with prostate cancer that has spread to other parts of the body. The drug is given alone or with another medicine (abiraterone) to see if it is safe and can slow the cancer. About 152 men will take part…

This trial asks whether removing lymph nodes during prostate cancer surgery lowers the chance of the cancer returning. Men with clear scans before surgery are randomly assigned to have lymph nodes removed or not. The study also tests other surgical tweaks, like how the incision i…

This trial tests whether proton therapy, a more precise form of radiation, causes fewer long-term bowel side effects than standard photon therapy in men with high-risk prostate cancer. Participants receive the same radiation dose and schedule, but one group gets protons and the o…

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This study tests whether a higher dose of proton radiation, focused on tumors seen on MRI, can better control high-risk prostate cancer. About 100 participants will receive radiation over 8-9 weeks, plus hormone therapy for 18 months. The goal is to lower the chance of cancer ret…

This trial is testing whether adding an immunotherapy drug called ipilimumab to the standard hormone therapy of abiraterone plus prednisone can help men with advanced prostate cancer that has spread and no longer responds to hormone treatment. The study includes men aged 18 and o…

This Phase 3 trial tests whether adding the experimental drug mevrometostat to standard enzalutamide can slow cancer growth better than current treatments in men with metastatic castration-resistant prostate cancer that has progressed after abiraterone. About 600 participants wil…

This study tests whether adding abiraterone and prednisone to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has come back after surgery or radiation. About 310 men will receive either hormone therapy or hormone therapy plus abirate…

This study tests whether adding the drug abemaciclib to standard treatment (abiraterone acetate plus prednisone) can help men with metastatic castration-resistant prostate cancer live longer without their cancer getting worse. About 393 participants will receive either the combin…

This trial tests whether a focal treatment called irreversible electroporation (IRE) can control localized prostate cancer as effectively as radical treatments, but with fewer side effects. IRE uses high-voltage electrical pulses to destroy tumor cells while sparing surrounding h…

This early-stage study tests a treatment called bipolar androgen therapy for men with advanced prostate cancer that no longer responds to standard hormone therapy. The treatment involves raising and lowering testosterone levels in a controlled way to try to slow cancer growth. Th…

This study follows over 800 men with non-metastatic castration-resistant prostate cancer who are already taking darolutamide as part of their normal care. Researchers are tracking side effects and how well the drug controls the cancer in real-world conditions, outside of a strict…

This phase 3 trial is testing whether giving the chemotherapy drug docetaxel more often but at a lower dose—every 2 weeks instead of every 3 weeks—can reduce severe side effects in men with metastatic hormone-sensitive prostate cancer. All participants also receive the standard c…

This study explores whether regular aerobic exercise, specifically walking about 300 minutes per week, can change certain biomarkers in the blood that are linked to cancer risk. Participants are adults who have completed all cancer therapy and have either clonal hematopoiesis (a …

This phase 3 trial tests whether focused high-intensity ultrasound (HIFU) can destroy low-risk prostate tumors without the side effects of radical treatments. Men aged 50-80 with a single, low-risk tumor will be randomly assigned to either HIFU or active surveillance (regular mon…

This study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…

This trial compares two ways of delivering radiation to the pelvis in men with unfavorable intermediate- or high-risk prostate cancer. One group receives the standard 25 sessions of radiation, while the other receives just 5 sessions with a higher dose per session. The goal is to…

This phase 2 trial tests whether adding cediranib to olaparib works better than olaparib alone for men with metastatic castration-resistant prostate cancer. Olaparib blocks DNA repair in cancer cells, while cediranib stops tumor blood vessel growth. The study involves 90 particip…

This trial asks whether giving a higher dose of radiation (80 Gy) is better than the standard dose (70 Gy) for men with aggressive prostate cancer who are also receiving hormone therapy. The study includes about 500 men with unfavorable prostate cancer features, such as advanced …

This Phase 3 trial tests whether adding the experimental drug saruparib to standard hormone therapy can slow cancer growth in men with metastatic prostate cancer that still responds to hormone treatment. About 1,889 men will receive either saruparib or a placebo, plus a hormone d…

This phase 2 trial tests whether adding enzalutamide to standard hormone therapy and chemotherapy can better control metastatic prostate cancer that still responds to hormones. About 40 men with advanced disease will receive all three drugs. The main goal is to see how many achie…

This study tests a new approach for men with intermediate-risk prostate cancer. First, doctors use electric pulses (IRE) to destroy tumor cells, followed by precise radiation (MRgRT). The goal is to see if this combination is safe and can keep cancer away for at least a year. Abo…

This trial investigates whether real-time motion management techniques—like triggered imaging and MLC tracking—can safely reduce the target margins used during radiotherapy for prostate and lung cancer. By adjusting the radiation beam to follow tumor movement, researchers aim to …

This early-stage trial tests a new drug called PSW-1025, which delivers a radioactive particle (astatine-211) directly to prostate cancer cells. The goal is to see if this targeted approach is safe and tolerable for men with castration-resistant prostate cancer, a form that no lo…

This early-stage trial is testing a new drug called IPH4502 in people with advanced solid tumors that have a specific protein called Nectin-4. The main goals are to check the drug's safety and find the best dose. About 145 participants will receive the drug, and researchers will …

This study tests whether giving the drug enoblituzumab for 12 weeks before prostate removal surgery can help prevent cancer from coming back in men with high-risk localized prostate cancer. About 219 men will be randomly assigned to receive either the drug or standard care. The m…

This early-stage trial tests whether combining two antibodies (anti-IGF-1R and anti-PD-1) can safely control metastatic castration-resistant prostate cancer (mCRPC) — a type that has stopped responding to hormone therapy. Seven men with advanced disease will receive the combinati…

This study observes how abiraterone acetate tablets work in real-world settings for Chinese men with metastatic prostate cancer. Researchers will track safety, side effects, and effectiveness, including PSA levels and survival. The goal is to understand how well the drug performs…

This phase 2 trial is testing whether combining three drugs—ZEN-3694, enzalutamide, and pembrolizumab—can shrink tumors or lower PSA levels in men with metastatic castration-resistant prostate cancer that has worsened despite prior treatment. ZEN-3694 blocks a protein that fuels …

This early-phase trial tests a new type of immune cell therapy (PSMA-UCAR T cells) in 3 men with advanced prostate cancer that no longer responds to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants must have me…

This early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, cartilage cancer, or brain tumors) that have specific IDH1 or IDH2 mutations. The main goal is to find a safe dose and see if the drug can shrink tumors. About …

This phase II trial tests a highly precise, short-course radiation therapy (SBRT) combined with hormone therapy for men whose PSA levels rise after prostate cancer surgery. The goal is to control the cancer while reducing side effects by delivering higher radiation doses in fewer…

This study tests whether different combinations of diet and exercise support tools—like educational materials, text messaging, and coaching—can improve outcomes for men with prostate cancer who choose surgery. Researchers will track PSA recurrence and quality of life over time. T…

This phase 2 trial tests whether adding apalutamide, abiraterone, and prednisone after chemotherapy can better control metastatic prostate cancer that still responds to hormone therapy. Seven men with high-risk, untreated disease are receiving this combination. The main goal is t…

This study tests whether a precise type of radiation (SBRT) alone can control unfavorable intermediate-risk prostate cancer, avoiding the need for hormone therapy. About 215 participants will receive SBRT, with the radiation dose guided by a genetic test (Decipher) to personalize…

This trial tests whether placing a dehydrated human amnion chorion membrane (dHACM) over the nerves during robot-assisted prostate removal helps men recover erectile function and urinary control sooner. The study enrolls men aged 40 to 80 with localized prostate cancer who have g…

This phase 2 study tests a combination of radiation, hormone therapy (ADT), and two drugs (abiraterone and olaparib) in 21 men with prostate cancer that has spread to a few spots in the body. The goal is to see if this approach can prevent the cancer from growing or spreading fur…

This study looks at whether a special program called Primary Care Connect (PC2) helps cancer survivors who also have conditions like high blood pressure, diabetes, or high cholesterol keep their heart risks under control during cancer treatment. About 266 adults with early-stage …

This phase 2 trial is testing whether giving the targeted drug olaparib (Lynparza) along with hormone therapy for 6 months before surgery can shrink or eliminate prostate cancer in men with high-risk disease and specific gene mutations. About 32 men will receive the treatment, th…

This study tests whether a precise, high-dose radiation boost using CyberKnife can improve outcomes for men with high-risk prostate cancer that has not spread. Participants receive standard hormone therapy and radiation to the prostate and nearby lymph nodes, followed by a CyberK…

This phase 3 trial tested enzalutamide (Xtandi) plus leuprolide in over 1,000 men with high-risk prostate cancer that had not spread but was progressing after initial treatment. The goal was to see if the combination could delay the cancer from spreading to other parts of the bod…

This observational study follows about 1,600 men with metastatic hormone-sensitive prostate cancer who are taking darolutamide plus hormone therapy, with or without chemotherapy. Researchers will track how many men have undetectable PSA levels after one year, as well as overall s…

This study looks at how prostate cancer treatments, especially hormone therapy, affect heart health. It includes two parts: one that follows men over time to track heart problems, and another that tests whether a program of healthy eating, exercise, smoking cessation, and medicat…

This phase 3 trial tests whether adding the targeted drug abemaciclib to standard hormone therapy (abiraterone plus prednisone) can delay cancer growth in men with high-risk prostate cancer that has spread to bones or organs. Participants receive either abemaciclib or a placebo a…

This study compares two types of radiation therapy for men with favorable or low-tier intermediate risk prostate cancer: low dose rate (LDR) brachytherapy, which uses permanent radioactive seeds, and high dose rate (HDR) brachytherapy, which uses temporary radioactive material. T…

This study looks at whether adding a precise type of radiation (SBRT) to intermittent hormone therapy can better control prostate cancer that has spread to a few places in the body. The trial involves 60 men whose cancer was detected by a special PET scan but not by standard scan…

This trial tests a minimally invasive treatment that uses microwaves to destroy only the cancerous part of the prostate, leaving healthy tissue intact. The goal is to control the cancer while avoiding common side effects of full prostate removal, such as urine leakage and erectil…

This study is for men whose prostate cancer has returned in the same area after they already had radiation and surgery. The researchers want to see if giving a very precise, high-dose radiation treatment (called SBRT) along with the diabetes drug metformin can safely control the …

This study tests whether a device called Calypso, which tracks the prostate's position in real time during radiation, can reduce long-term side effects compared to standard image-guided radiation. 74 men with low- or intermediate-risk prostate cancer took part. The goal is to see…

This study tests a biodegradable balloon, called a rectal spacer, placed between the prostate and rectum before radiation therapy for prostate cancer. The goal is to see if it safely reduces radiation exposure to the rectum, potentially lowering side effects. Up to 150 men with l…

This study is testing whether giving high-dose radiation only to the tumor area (focal HDR brachytherapy) can control early-stage prostate cancer while causing fewer side effects than treating the whole gland. Sixty men with low- or favorable intermediate-risk prostate cancer wil…

This was a planned early-stage trial to test a new oral drug called ERW316, alone or with hormone therapies, in people with advanced breast cancer or other solid tumors. The study aimed to find a safe dose and check for side effects. However, the trial was withdrawn before any pa…

This study looks at whether a whole-food, plant-based diet can help overweight or obese men with prostate cancer who are on hormone therapy (ADT) control their weight and reduce inflammation. About 76 men will either receive free plant-based meals at home or standard nutrition ad…

This study tests a device called Vanquish that uses water vapor (steam) to destroy prostate cancer tissue in men with intermediate-risk, localized prostate cancer. The goal is to control the cancer while avoiding common side effects like incontinence and impotence. About 400 men …

This study compares two surgical methods for treating benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate. The trial involves 140 men aged 50-80 with prostates of 80 mL or larger who are candidates for holmium laser enucleation. One group receives the …

This phase 2 trial tests whether giving a combination of enteric-coated aspirin, rintatolimod, and interferon-alpha 2b before prostate cancer surgery can boost the immune system's attack on tumors. The study involves 12 men with localized prostate cancer who are scheduled for sur…

This phase II trial is testing a combination of two drugs—sEphB4-HSA and pembrolizumab (Keytruda)—in 70 people with advanced bladder or prostate cancers that have not responded to standard treatments. The goal is to see if the combo is safe and can shrink tumors. Participants rec…

This study tests whether adding a targeted radiation drug (177Lu-PSMA-617) to standard hormone therapy can help men whose prostate cancer has spread but still responds to hormones. About 1,140 men are taking part. The goal is to see if the combination slows cancer growth and exte…

This early-phase study tests a new oral drug called E7386 in about 60 adults with advanced solid tumors (like desmoid tumors) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also watch for any tu…

This phase 2 trial is testing a drug called sacituzumab govitecan in 31 men with metastatic castration-resistant prostate cancer that has worsened despite hormone therapy. The drug works like a smart bomb, delivering chemotherapy directly to cancer cells. Researchers are measurin…

This early-phase trial tests a new type of immunotherapy for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are genetically modified in a lab to recognize and attack cancer cells that carry a …

This phase 2 trial tests a DNA vaccine (pTVG-HP) plus the immunotherapy drug nivolumab in 19 men whose prostate cancer has returned after surgery but has not spread. The goal is to see if the combination can safely lower PSA levels to undetectable and delay cancer spread. Partici…

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This phase II trial tests whether adding precise radiation (SBRT) to the hormone therapy darolutamide can delay cancer progression in men with castration-resistant prostate cancer that has only a few new spots of growth. The study involves 66 participants and measures how long it…

This phase 2 trial tests whether giving a radioactive drug (177Lu-PSMA) before precise radiation (SBRT) can better control prostate cancer that has come back in 1 to 5 spots. About 93 men with recurrent prostate cancer will receive either SBRT alone or the drug first, then SBRT. …

This study tests a newer, highly precise radiation technique for men with high-risk prostate cancer. The treatment delivers a strong dose to the pelvic lymph nodes while boosting radiation to the prostate itself. Researchers want to see if this approach controls the cancer better…

This Phase 3 trial compares two hormone therapies (GnRH antagonist vs GnRH agonist) given alongside radiation for men with very high-risk localized or locally advanced prostate cancer. The main goal is to see which combination better delays cancer progression. The study enrolled …

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This study aimed to see if giving the immunotherapy drug pembrolizumab before radical prostatectomy could reduce lymph node invasion in high-risk prostate cancer patients. Participants would have received three doses of the drug before surgery. However, the study was withdrawn be…

This study looks at using heat or cold to destroy small clusters of prostate cancer that have spread to other parts of the body. It is for men who cannot have standard radiation therapy. The goal is to control the cancer with a quick, low-risk procedure that allows a fast recover…

This early-phase trial tests whether combining two oral targeted drugs, talazoparib and tazemetostat, is safe and can shrink or slow the growth of metastatic castration-resistant prostate cancer (mCRPC). About 35 adults with advanced prostate cancer that has spread and is no long…

This early-phase trial tests whether giving higher doses of radiation to the prostate in fewer sessions (while also treating pelvic lymph nodes) is safe for men with intermediate- to high-risk prostate cancer. The study enrolls 18 adults and uses proton beam therapy delivered fou…

This study tests the drug olaparib in 51 men whose prostate cancer has returned after surgery and is at high risk of spreading. Olaparib works by blocking a repair process that cancer cells rely on, especially those with certain DNA faults. The main goal is to see if the drug can…

This study tests whether adding the immunotherapy drug atezolizumab and targeted radiation (SBRT) to standard hormone therapy (abiraterone, prednisone, and leuprolide) is safe and works better for men with newly diagnosed metastatic prostate cancer that hasn't been treated yet. T…

This phase 2 study tests nivolumab (Opdivo) in 29 men with high-risk prostate cancer that has returned after initial treatment, shown by rising PSA levels. The drug works by helping the immune system recognize and attack cancer cells. The main goal is to see if nivolumab can cont…

This trial gives men with metastatic castration-resistant prostate cancer (mCRPC) continued access to the experimental drug ZEN003694, often combined with enzalutamide (Xtandi), if they are already seeing benefits from it in a previous study. About 40 participants will be enrolle…

This study tests whether adding the drug darolutamide before and after surgery helps men with high-risk or locally advanced prostate cancer. About 240 men will either have surgery alone or surgery plus the drug. The goal is to see if the drug delays the cancer from coming back or…

This phase 3 trial tests whether adding enzalutamide to standard hormone therapy and radiation can delay cancer spread in 802 men with high-risk localized prostate cancer. Participants receive either enzalutamide or a conventional anti-androgen alongside hormone therapy and radia…

This study looks at men whose prostate cancer has come back in a few spots (oligometastatic) and who have certain gene mutations. It compares standard care (hormone therapy plus radiation) against the same treatment plus a 6-month course of two drugs (niraparib and abiraterone wi…

This study was designed for men with high-risk prostate cancer who are scheduled for prostate removal surgery. It planned to give a combination of three immunotherapy drugs (N-803, ETBX-071, and M-CENK) both before and after surgery to see if it could help prevent the cancer from…

This study compares a new, less invasive treatment called Aquablation, which uses a high-speed waterjet to remove prostate tissue, to standard surgery (radical prostatectomy) for men with localized prostate cancer. About 280 men will be randomly assigned to one of the two treatme…

This study was designed for men with high-risk prostate cancer who cannot have surgery. It planned to combine three experimental drugs (N-803, ETBX-071, and M-CENK) with radiation to boost the immune system's attack on cancer. Researchers aimed to see if the treatment could elimi…

This study tests whether adding darolutamide to standard hormone therapy and radiation can delay cancer spread in men with very high-risk localized prostate cancer. About 1,100 men are participating in this phase 3 trial. The goal is to see if the combination helps keep the cance…

This phase II trial tests whether using MRI to map the exact location of recurrent prostate cancer after prostatectomy allows doctors to safely deliver a higher radiation dose to the tumor while sparing healthy tissue. The study enrolled 37 men whose PSA levels rose after surgery…

This study tests a combination of a targeted drug (niraparib), hormone therapy, and precise radiation for men with high-risk or node-positive prostate cancer. The goal is to find the safest dose and see if this approach improves the chance of staying cancer-free for three years. …

This small study tests whether a 3D ultrasound system can help doctors place extra radioactive iodine seeds precisely into prostate tumors. Fifteen men with low- or intermediate-risk prostate cancer will receive the boost during standard brachytherapy. The main goal is to see if …

This early-stage study tests a radioactive drug called 225Ac-PSMA-617 in men with PSMA-positive prostate cancer that has stopped responding to hormone therapy. The goal is to find a safe dose and see if it can help control the cancer, even in men who have already received a simil…

This study tests a low dose of a radioactive drug called 225Ac-LNC1011 in 16 men with a type of advanced prostate cancer that has stopped responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly. The goal is to see if it safely shrin…

This study tests a combination of two radiation techniques—brachytherapy and SBRT—guided by MRI for men with unfavorable prostate cancer. The goal is to achieve high cancer control rates while keeping serious side effects low. About 40 participants will be enrolled to see if this…

This phase 2 trial tests a combination of hormone therapy, external beam radiation, and MRI-guided internal radiation implants for men with unfavorable-intermediate to very high-risk prostate cancer. The goal is to see if this precise approach causes fewer urinary side effects th…

This study tests whether giving a mix of hormone-lowering medications (apalutamide, abiraterone, prednisone, and a GnRH drug) for a few months before surgery can shrink very high-risk prostate cancer and reduce the chance of it coming back. About 102 men with localized or low-vol…

This trial was designed to test whether robotic telesurgery—where a surgeon operates a robot from a different location—could safely treat prostate cancer using high-intensity focused ultrasound (HIFU). The study was withdrawn before enrolling any participants, so no data on safet…

This study compares two types of brachytherapy (radiation implants) for localized prostate cancer: low-dose-rate (seed) implants and high-dose-rate (temporary) implants. About 334 men will receive one of the two treatments. Researchers will measure how well each controls cancer a…

This study tests whether giving a higher dose of radiation (up to 81 Gy) to men with high-risk prostate cancer can better control the disease without causing too many side effects. About 251 men who also need hormone therapy will receive targeted radiation using a precise techniq…

This study tests a precise form of proton radiation for men with low- or intermediate-risk prostate cancer. The goal is to see if this approach causes fewer severe side effects than standard X-ray-based radiation. About 61 men will receive 5 treatments over 10 days and be monitor…

This early-stage trial tests whether combining a targeted radiation drug (177Lu-PSMA-617) with chemotherapy (carboplatin) is safe and can shrink tumors in men with metastatic castration-resistant prostate cancer. About 37 men will receive the combination to find the best dose and…

This trial compares two common radiotherapy schedules for prostate cancer: 70 Gy in 28 sessions versus 60 Gy in 20 sessions. Both are already used in clinics, but it is not clear which one works better or causes fewer side effects. The study involves 400 men with early-stage pros…

This phase 2 trial tests whether a radioactive antibody called 177Lu-J591, combined with the hormone-blocking drug ketoconazole, can prevent prostate cancer from spreading in high-risk patients. The study enrolls 55 men whose PSA is rising despite hormone therapy but who have no …

This study tests a combination of four drugs (nivolumab, ipilimumab, cabazitaxel, and carboplatin) in 41 men with a hard-to-treat form of prostate cancer. The goal is to see if this mix can slow or stop cancer growth. Participants receive up to 10 cycles of the combo, then contin…

This early-stage study tests a new radioactive drug called AB001 in 80 men with advanced prostate cancer that has stopped responding to hormone therapy. The drug delivers a powerful alpha radiation dose directly to cancer cells. The main goals are to check safety and find the bes…

This pilot study tests two ultra-high-dose radiation schedules in 31 men with intermediate-risk prostate cancer. One group gets five high-dose sessions over a week; the other gets a single massive dose. The goal is to see if these shorter treatments are safe and can control the c…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This phase II trial tests whether adding the immunotherapy drug durvalumab to precise radiation (SBRT) can better control prostate cancer that has returned and spread to a few spots (oligometastases). About 96 men with hormone-sensitive prostate cancer will be randomly assigned t…

This study tests whether a combination of two drugs, olaparib and AZD6738, can shrink tumors or lower PSA levels in men with advanced prostate cancer that no longer responds to hormone therapy. About 49 men with metastatic castration-resistant prostate cancer will receive the dru…

This study tests whether giving a precise, high-dose radiation treatment (SBRT) before prostate removal surgery is safe and effective for men with high-risk prostate cancer. Sixteen men with aggressive prostate cancer (Gleason score 8 or higher or signs of spread) will receive ra…

This study compares two drugs, mannitol and nitroglycerin, given during robotic prostate or bladder surgery to prevent acute kidney injury. The surgery can reduce blood flow to the kidneys, and these drugs may help protect them. 90 adults with normal or mildly reduced kidney func…

This study tests whether using a lung ultrasound during robotic prostate or bladder surgery can help doctors set the breathing machine to the right pressure, reducing lung collapse and other breathing problems. 88 adults with mild or no lung disease are enrolled. The approach is …

This study tests whether a very short course of MRI-guided radiation (just 5 sessions) is safe and effective for men with low- or intermediate-risk prostate cancer. Traditional radiation can take 7-8 weeks, but this approach aims to cut that time dramatically. The trial involves …

This study tests whether using advanced MRI scans to guide radiation therapy can reduce side effects for men with localized prostate cancer. Depending on their MRI results, patients receive either a short course of radiation or a longer treatment with a targeted boost to visible …

This study looks at whether testosterone levels can return to normal after two years of treatment with relugolix and darolutamide in men with hormone-sensitive prostate cancer. About 33 participants will receive the drug combination and be monitored for testosterone recovery and …

This study tests a drug called palbociclib in 19 men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if it can shrink tumors or lower PSA levels, and to check for side effects. Researchers also look for markers to predict who might ben…

This study follows 3000 men with prostate cancer to compare how proton therapy and standard photon radiation affect quality of life and side effects like bowel urgency. Participants receive standard care at proton or photon centers, and researchers track bowel, urinary, and sexua…

This study tests whether using MRI guidance to deliver an extra dose of radiation directly to the tumor can improve prostate cancer treatment. Forty men with localized prostate cancer will receive standard radiation to the whole prostate plus a targeted boost to the visible tumor…

This phase 2 trial tests whether a shorter, more intense radiation course (SBRT) causes fewer side effects than standard daily radiation (IMRT) in men with high-risk prostate cancer. Both groups also receive hormone therapy. The study will compare side effects, quality of life, a…

This study tests whether giving radiation in just 5 treatments over 2 weeks is as safe and effective as the standard 20 treatments over 4 weeks for men whose prostate cancer has come back after surgery. The 134 participants will be randomly assigned to one of the two schedules. T…

This phase 1 trial is testing a precise, high-dose radiation technique called SABR for men with high-risk prostate cancer. The goal is to find the highest safe dose to the prostate and pelvic lymph nodes while monitoring side effects. Sixty participants will receive five radiatio…

This study tests whether giving an extra-high dose of radiation to the most aggressive parts of prostate tumors, guided by MRI, can better control cancer while reducing side effects. About 164 men with prostate cancer will receive either the standard radiation or the standard plu…

This study tests a special type of radiation called stereotactic body radiotherapy (SBRT) for men with high-risk prostate cancer that hasn't spread. The treatment delivers a strong, focused dose of radiation to the tumor to kill cancer cells while sparing healthy tissue. Research…

This early-phase study tests a new type of immunotherapy for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are genetically modified to better recognize and attack prostate cancer cells while …

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This study tests a new way to deliver high-dose radiation (SABR) for low- and intermediate-risk prostate cancer. The technique, called SUPR-SABR, is designed to avoid the urethra, rectum, and pudendal artery to reduce urinary and bowel side effects. About 42 men will receive five…

This study tests whether giving a combination of two hormone therapies (leuprorelin and darolutamide) for 24 weeks before prostate removal surgery can reduce or eliminate cancer more effectively than either drug alone. It involves 144 men with intermediate to high-risk prostate c…

This study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…

This phase III trial tests whether adding rucaparib to standard enzalutamide therapy helps men with metastatic castration-resistant prostate cancer live longer or delay cancer growth. The study involves 61 participants and compares the combination against enzalutamide alone. Rese…

This phase II trial is testing whether combining antiandrogen drugs (leuprolide, apalutamide, abiraterone) with precise radiation (SBRT) can control prostate cancer that has come back and spread to a few other spots in the body. The study enrolls 28 men whose cancer has 1-5 visib…

This study compares two radiation methods for men with low- or intermediate-risk prostate cancer: low dose rate (permanent seed implants) and high dose rate (temporary radioactive needles). The main goal is to see which approach better preserves urinary quality of life. About 140…

This study tests a robotic system that uses a high-pressure water jet to remove prostate tissue in men with localized prostate cancer and trouble urinating. The goal is to see if the procedure is safe and works well. About 125 men will be followed for one year after treatment.

This study compares three different radiotherapy techniques for prostate cancer: standard treatment, a shorter course (SBRT), and a booster approach. Over 500 participants are being followed to see which method best controls cancer while minimizing side effects and preserving qua…

This trial compares two types of brachytherapy boost (HDR vs LDR) given alongside external beam radiation for intermediate- and high-risk prostate cancer. The goal is to see which one provides better cancer control and quality of life with fewer side effects. About 195 men are ta…

This program offers expanded access to NanoPac, a cancer treatment, for people with advanced pancreatic, prostate, or lung cancer who cannot join ongoing clinical trials. The goal is to provide the drug to those who have no other options. However, the program is no longer availab…

This study compares a standardized active surveillance protocol to usual care for men with low-risk prostate cancer. The goal is to see if a clear set of rules for when to start treatment can reduce unnecessary treatments and side effects without raising the risk of cancer spread…

This phase II trial tests whether using PSMA PET scans to select patients with castration-resistant prostate cancer that has spread to bones can improve the effectiveness of radium-223 therapy. Radium-223 is a radioactive drug that targets bone tumors. The study involves only 2 p…

This study looks at whether removing the prostate and nearby lymph nodes, in addition to standard drug therapy, helps men with prostate cancer that has spread to a few bones live longer and delay the cancer becoming resistant to treatment. About 452 men with intermediate- or high…

This phase 3 trial tests a radioactive drug called Lu-177-PNT2002 in 455 men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. The main goal is to see if it delays canc…

This study tests a new surgical technique for treating enlarged prostate in men who also have a penile implant. The standard approach through the urethra can damage the implant, so surgeons are trying an alternative route through the lower belly. The study will enroll 80 men and …

This study is for men whose prostate cancer has returned after surgery, shown by a rising PSA. It compares standard hormone therapy plus radiation to a stronger version that adds enzalutamide. The goal is to see if the enhanced treatment keeps the cancer from progressing longer. …

This trial is testing a new way to treat prostate cancer that returns after the prostate has been removed. It combines a very short course of highly targeted radiation (just 5 sessions) with 6 months of hormone therapy. The goal is to see if this approach can control the cancer w…

This phase 3 trial tests whether giving denosumab every 12 weeks instead of every 4 weeks can still prevent bone complications (like fractures or spinal cord compression) in people with metastatic breast or prostate cancer. About 1,380 participants with bone metastases will be ra…

This study was designed to test two experimental drugs, AAA602 and AAA802, which deliver radiation directly to prostate cancer cells. Men with high-risk localized prostate cancer would have received these drugs before surgery to remove the prostate and nearby lymph nodes. The goa…

This study tests an experimental drug called [Ac-225]-PSMA-62 in people with prostate cancer that has spread to other parts of the body. The drug delivers a small amount of radiation directly to cancer cells. The main goals are to find the safest dose and to see if it can shrink …

This phase 3 study tests whether combining two drugs—cabozantinib (a targeted therapy) and atezolizumab (an immunotherapy)—works better than standard hormone therapy for men with metastatic castration-resistant prostate cancer that has progressed after one prior hormone treatment…

This study tests whether a daily high-dose omega-3 supplement (fish oil) can slow the rise of PSA levels in men whose prostate cancer has returned after initial treatment. About 40 men with a rising PSA but no spread will take either the supplement or a placebo for one year. The …

This pilot study is testing whether robot-assisted prostate removal for localized prostate cancer can be safely performed as outpatient surgery, meaning patients go home the same day. Twenty men will be enrolled and followed for one month to see if they can avoid a conventional h…

This study looks at whether adding a high-precision type of radiation called SBRT to usual cancer treatments (like hormone therapy or chemo) can delay cancer growth in people with breast, lung, or prostate cancer that has spread to 1 to 5 bones. About 168 adults aged 18-75 with g…

This study looks at how well a new robotic surgery system (Medtronic Hugo) works for urologic procedures like removing prostate, bladder, or kidney tumors. About 144 adults will have surgery with the robot, and doctors will check if the surgery is completed without switching to a…

This early-phase study tested a combination of enzalutamide (a hormone-blocking drug), radiation therapy, and standard hormone therapy in 25 men with intermediate or high-risk prostate cancer. The main goal was to check for side effects and find the best way to give the treatment…

This phase 2 trial tests whether taking omega-3 (EPA) supplements can reduce inflammation and slow cancer cell growth in men with high-risk prostate cancer who choose surgery. 130 participants will take either EPA capsules or a placebo for 14 months, starting before surgery. Rese…

This study tested whether a shorter, more intense radiation schedule (5 sessions) works as well as the standard longer schedule (26 sessions) for men with prostate cancer. The goal was to see if the shorter treatment could control the cancer just as well, based on PSA levels afte…

This study tests a focused radiation technique called HDR brachytherapy for men whose prostate cancer has come back after earlier radiation treatment. The radiation is placed directly into the cancerous area and removed after a short time, aiming to spare healthy tissue. The tria…

This study tests a device that uses ultrasound energy guided by MRI to precisely destroy prostate cancer tumors while sparing healthy tissue. 62 men with localized prostate cancer will receive the treatment. The goal is to see if this approach is safe and effective at controlling…

This phase 3 trial compares enzalutamide alone versus enzalutamide plus radium-223 in 446 men with castration-resistant prostate cancer that has spread to bone. The goal is to see if the combination delays cancer progression better than enzalutamide alone. Participants must have …

This study follows 80 prostate cancer patients who previously received a BioProtect balloon implant during radiation therapy. Researchers are checking for long-term side effects in the bladder and bowel, and how patients' quality of life holds up over time. The goal is to make su…

This phase 3 trial compares a new, shorter course of radiation (ultra-hypofractionated) to the standard longer course for men with prostate cancer that has spread to lymph nodes. Both groups also receive a brachytherapy boost and hormone therapy. The study aims to see if the shor…

Surgeons removing a prostate for cancer can struggle to tell cancerous tissue from healthy tissue, and cancer left at the edge of the removed gland is usually found only days later under a microscope. This pilot study at Geneva University Hospitals tests whether a PET/CT scanner …

Researchers at Herlev Hospital are studying whether multiparametric MRI can help doctors decide which men with low-risk prostate cancer can safely stay on active surveillance instead of getting treatment. The trial enrolls 150 men with newly diagnosed low-risk prostate cancer who…

This study is testing whether a special type of MRI (multiparametric MRI) can better identify which men with low-risk prostate cancer can safely delay treatment. About 200 men already on active surveillance will receive the MRI, and if suspicious areas are found, they will get ad…

This study aims to develop an artificial intelligence (AI) model that combines two advanced imaging techniques—multiparametric MRI and PSMA PET/CT—to more accurately diagnose prostate cancer. By analyzing data from up to 1,500 patients, the AI model is designed to identify clinic…

This study looks at whether a special type of MRI, called multiparametric MRI, can more accurately determine the stage of prostate cancer in people who are newly diagnosed and planning surgery. The goal is to see if this imaging method helps doctors find aggressive cancers and ma…

Researchers are running a registry to see how a PET scan using PYLARIFY (piflufolastat F18) affects real-world care for men with prostate cancer. The study will follow 500 men for up to 5 years, collecting data every 6 months on their diagnosis, treatment, and outcomes. The goal …

Researchers are studying whether a blood test can detect prostate cancer by finding prostasomes, tiny particles that prostate cancer cells release into the blood. The trial enrolls men with elevated PSA levels or diagnosed prostate cancer who have not yet received treatment. The …

This study compares a new radioactive tracer called 18F-DCFPyL with standard tracers to see if it can better detect where prostate cancer has spread in the body. About 96 men with metastatic prostate cancer will receive both tracers and undergo PET/CT scans. The goal is to measur…

This phase 2 trial tests whether a radioactive tracer called 18F-DCFPyL can improve PET/CT scans for men with high-risk or recurrent prostate cancer. About 360 men will receive the tracer and undergo imaging to see if it more accurately finds cancer outside the prostate or after …

Researchers at Northwestern University are testing an artificial intelligence tool that reads prostate MRI scans to find suspicious lesions. The goal is to see whether this AI can detect clinically significant prostate cancer as well as or better than the standard PIRADS scoring …

This study tests whether a new radioactive tracer called 68Ga-HBED-CC-PSMA can detect prostate cancer that has returned after initial treatment, even when PSA levels are very low and standard scans show nothing. Men with biopsy-proven prostate cancer who have been treated with su…

This study tests a new imaging agent called 68Ga-FAPI-46, which targets a protein (FAP) found around tumor cells. Researchers want to see where this tracer goes in the body and whether it can highlight prostate cancer on PET scans. About 30 people with prostate cancer who are alr…

This study compares two methods for detecting serious prostate cancer: MRI fusion biopsy and micro-ultrasound (ExactVu). Researchers want to see if micro-ultrasound can find dangerous cancers as well as MRI, and if it can be used in communities with limited healthcare access. The…

This study tests a new type of PET/CT scan using a radioactive tracer called copper Cu 64 PSMA I&T to see if it can accurately find prostate cancer that has spread to pelvic lymph nodes. About 439 men with newly diagnosed, aggressive prostate cancer who are planning to have their…

This study is testing a new blood test that looks at RNA from tiny particles called exosomes to diagnose prostate cancer. Researchers will enroll 1,600 men with elevated PSA levels or other signs of prostate cancer. The goal is to see if this test can accurately detect cancer and…

This study is testing whether a new blood test called ClarityDX Prostate can better identify men who have clinically significant prostate cancer. The test is given to men aged 40-75 with elevated PSA levels (3 ng/mL or higher) who are already scheduled for a prostate biopsy. Rese…

This trial tests whether combining a blood test that analyzes DNA fragments (cfDNA) with MRI scans can better detect prostate cancer in men with borderline PSA levels (4–10 ng/mL). Researchers aim to build a prediction model that could reduce unnecessary biopsies. The study invol…

This trial is testing whether a blood-based risk score called ClarityDX Prostate can help doctors decide which men truly need an MRI or biopsy when checking for prostate cancer. The test combines standard PSA levels with age and other factors to give a personalized risk estimate.…

This study compares two imaging methods—multiparametric ultrasound (mpUS) and multiparametric MRI (mpMRI)—to see which better detects clinically significant prostate cancer in men scheduled for their first biopsy. Participants receive both scans before biopsy, and if either shows…

This trial evaluates a new imaging technique called 18F-PSMA-1007 PET/CT for detecting prostate cancer in men with elevated PSA levels (4-20 ng/mL) or abnormal rectal exams. The scan uses a radioactive tracer that targets a protein common on prostate cancer cells, aiming to impro…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This study tests an artificial intelligence system that combines blood tests, lab data, and ultrasound images to better diagnose prostate cancer in men with borderline PSA levels (4-10 ng/mL). The goal is to reduce unnecessary biopsies by accurately identifying who truly has canc…

This study tests whether combining a special MRI analysis (called Habitat Risk Score) with blood and urine tests can more accurately rule out aggressive prostate cancer than the standard MRI reading. About 289 men with elevated PSA or abnormal exams will be enrolled. The goal is …

This study aimed to see if adding a two-minute distortion correction to standard prostate MRI scans could improve image quality and help doctors find tumors more accurately. It was designed for men who already had an MRI and biopsy. However, the study was withdrawn before any par…

This trial compares two biopsy methods for diagnosing prostate cancer in African American and white men with elevated PSA. One group gets a standard 12-core random biopsy, the other gets an MRI-guided fusion biopsy. The goal is to see which method more accurately detects clinical…

This study tests whether a new PET-CT scanner (RefleXion RMRS) can produce clear images of prostate cancer using a standard radioactive tracer. About 34 patients will receive both the standard scan and the new scan. If the new scanner works well, it may allow imaging and radiatio…

This study tests whether a special PET/CT scan (68Ga-PSMA-11) can help doctors plan more precise radiation for men whose prostate cancer has come back after surgery. About 193 men with a rising PSA level will be randomly assigned to have their radiation plan based on either the n…

This phase 3 study tests a new type of PET scan (64Cu-SAR-bisPSMA) to see if it can better detect prostate cancer that has come back after initial treatment. The study involves 220 adults with a rising PSA level after surgery or radiation. The goal is to improve detection so doct…

This study tests whether a special PET/CT scan using a radioactive tracer called 18F-DCFPyL can better detect aggressive prostate cancer in men with elevated PSA levels. About 150 men with PSA between 2-10 ng/mL and no prior biopsy will receive the scan before their standard biop…

This study looks at the best timing for a special PET scan (rhPSMA-7.3) to detect prostate cancer that has come back after prostate removal surgery. Men with a rising PSA level will get one or two scans to see when the cancer is most visible. The goal is to find the cancer early …

This study compares two types of urine samples—expressed prostatic secretion (EPS) and post-massage urine (PMU)—to see which one better predicts whether a prostate biopsy will find cancer. About 243 men scheduled for a prostate biopsy will provide both samples, and researchers wi…

This early study tests a new imaging agent called 89Zr-DFO-YS5, which attaches to a protein (CD46) found on aggressive prostate cancer cells. Thirty men with advanced prostate cancer will receive the agent and then undergo PET scans to see if the cancer lights up. The goal is to …

This pilot study is testing the world's first total-body PET/CT scanner (EXPLORER) to see if it can improve cancer imaging. Researchers will scan 9 people with prostate cancer, breast cancer, or neuroendocrine tumors using FDA-approved radiotracers. The goal is to measure how wel…

This pilot study is testing a new screening pathway for prostate cancer in men aged 55-65. Instead of relying only on PSA blood tests, participants with elevated PSA will also get a risk assessment and an MRI. The goal is to better distinguish between slow-growing cancers that do…

This study looks at whether combining PSMA-PET/CT and MRI scans can more accurately determine the extent of prostate cancer in men with intermediate- or high-risk disease. Researchers will compare scan results with tissue samples from 600 men who had their prostate removed. The g…

This study tests whether adding a PSMA PET scan helps doctors better diagnose significant prostate cancer in men whose MRI results are unclear or negative. About 660 men with no prior prostate cancer or biopsy will be randomly assigned to receive either standard care or an additi…

This study tests whether analyzing ultrasound images with computer software (radiomics) can better predict prostate cancer during a targeted biopsy. About 464 men aged 55 and older with suspicious prostate findings will participate. The goal is to see if this method finds more ca…

This study tests a special PET scan (18F-DCFPyL) to see if it can find prostate cancer spread that standard scans miss. Fifty men with castration-resistant prostate cancer starting enzalutamide will get the new scan. The goal is to better detect and monitor metastases, which coul…

This study looks at whether men with certain gene mutations (DRG) could benefit from a more tailored screening for prostate cancer. Researchers will test a combination of a blood test (PHI) and a special MRI scan in 320 men with or at risk for prostate cancer. The goal is to see …

This study tests a new software that combines MRI images with real-time ultrasound to guide prostate biopsies. The goal is to help doctors more accurately detect and locate aggressive prostate cancer early. About 100 men scheduled for a standard prostate biopsy will take part. Th…

This study is testing whether a special PET scan using PYLARIFY can find prostate cancer that has spread beyond the prostate in men with favorable intermediate risk cancer. About 274 men will receive one injection and scan, then be followed for up to a year. The goal is to see if…

This early study tests a new radioactive tracer called [68Ga]DOTA-IR-780-C-4 for PET/CT imaging in men with PSMA-positive prostate cancer. The goal is to see if it can accurately detect primary and metastatic lesions. Only 5 participants are enrolled, and they will receive the tr…

This study follows 7,500 men aged 50-74 to see which prostate cancer screening method works best over time. Some men were invited for a standard PSA test, while others had a newer approach using PSA plus a biomarker test and MRI. Researchers will track prostate cancer deaths, dia…

This early-stage study tests an experimental vaccine designed to prevent cancer in adults with BRCA1 or BRCA2 gene mutations. The vaccine is given alone or with another drug, followed by a mild electric pulse to help it enter cells. Researchers want to see if it is safe and wheth…

Researchers are studying whether placing a spacer between the prostate and rectum can protect the rectum during proton beam therapy for localized prostate cancer. The trial enrolls up to 50 adults with early-stage prostate cancer who are scheduled for this radiation. Participants…

This trial tests a biodegradable gel called SpaceOAR Vue that is injected between the prostate and rectum before radiation therapy. The gel temporarily pushes the rectum away to reduce radiation damage. About 500 men with intermediate-risk prostate cancer will be randomly assigne…

This study compares two types of radiation therapy for low- or intermediate-risk prostate cancer: proton therapy (PBT) and intensity-modulated radiation therapy (IMRT). Both are thought to be equally effective at treating the cancer, but it's unclear which causes fewer side effec…

This study looks at whether combining exercise, supportive counseling, and a stimulant drug (methylphenidate) can help reduce severe fatigue in prostate cancer patients who are receiving radiation and hormone therapy. About 175 adults with prostate cancer and daily fatigue will b…

This early-stage study tests a high-precision radiation treatment called stereotactic body radiation therapy (SBRT) for men whose prostate cancer has returned after surgery. The main goal is to find the safest dose by monitoring side effects in 26 participants. The treatment deli…

This trial tests a proactive care model for men with metastatic hormone-sensitive prostate cancer who are taking the drug apalutamide. The model focuses on four areas: education, prevention, management, and follow-up, to help patients understand their treatment, reduce side effec…

This study tests a new way to deliver radiation for prostate cancer that hasn't spread. By using real-time motion tracking during treatment, doctors hope to target the tumor more precisely and reduce common side effects like urinary and bowel problems. About 80 men with early-sta…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This phase II trial tests whether time-restricted eating (intermittent fasting) can reduce side effects from radiation or chemoradiation in people with prostate, cervical, or rectal cancers. About 49 participants will either follow a time-restricted eating plan or receive standar…

This phase 2 study tests whether acupuncture can improve memory, focus, and thinking problems (often called 'chemo brain') in people who have had breast, colorectal, prostate, or gynecological cancer. About 48 participants will receive either real acupuncture or sham (fake) acupu…

This pilot study tests a lifestyle intervention called Watchful Living for Black and Hispanic prostate cancer patients on active surveillance and their partners. The program includes nutrition counseling, an exercise plan, and telephone coaching to improve quality of life, physic…

This study tests the DISCO app, designed to help cancer patients talk with their doctors about treatment costs. About 254 adults newly diagnosed with breast, prostate, lung, or colorectal cancer will use the app to become more confident in asking cost-related questions. The goal …

This study compares group telemedicine appointments to individual video visits for men with prostate cancer who are on active surveillance. Researchers want to see if the group format is practical and acceptable, and how it affects patient satisfaction and quality of life. The st…

This study tests whether a 12-week home exercise program, guided by telehealth check-ins, can reduce fatigue in cancer survivors living in rural Colorado. Participants follow a personalized plan of aerobic and resistance exercises, with intensity adjusted based on their progress.…

This trial tests whether an AI-powered chatbot can help reduce anxiety and improve coping in men about to have prostate cancer surgery. Participants will either receive standard preoperative communication or also have access to a large language model (LLM) that answers their ques…

This study tests whether adding an extra numbing injection inside the prostate can reduce pain during a prostate biopsy. Fifty men undergoing the procedure will receive either standard numbing of the skin or the standard plus the extra injection. Pain levels are measured before, …

This study tests whether using advanced MRI and daily CT scans during radiation therapy for low- to intermediate-risk prostate cancer can reduce side effects like bowel, bladder, and erectile problems. About 99 men will receive standard radiation but with more precise imaging to …

This study tests whether a structured home-based exercise program combining strength and aerobic training can improve quality of life, fitness, and immune function in 150 men with prostate cancer. Participants are randomly assigned to either the exercise program or usual care. Th…

This study tests whether eating a low-calorie diet before chemotherapy can reduce side effects like fatigue, nausea, and mouth sores, and also improve how well the treatment works. About 130 people with breast or prostate cancer will be randomly assigned to either follow the diet…

This study looks at whether men with prostate cancer can have robotic surgery to remove the prostate and go home the same day, instead of staying in the hospital overnight. Researchers will check how many patients agree to try this approach and how well it works. The goal is to s…

This phase 2 trial is testing whether a special type of radiation therapy (SAbR) that avoids the nerves involved in erections can help preserve sexual function in men with localized prostate cancer. About 124 men will be randomly assigned to receive standard SAbR or a version tha…

This study tests a new radiation technique for men whose prostate cancer returns after surgery. Instead of many standard treatments, this approach uses daily scans to adjust the radiation beam precisely, potentially reducing side effects and shortening the number of sessions. Abo…

This study looks at whether giving a numbing injection (called a TAP block) early or late during robotic prostate surgery helps reduce pain afterward. About 94 men with prostate cancer will take part. The goal is to find the best timing to lower pain scores and the need for stron…

This study tests a personalized rehabilitation program designed to help men recover their sexual quality of life after prostate removal for cancer. About 135 men will take part, with half receiving the program and half receiving standard care. The goal is to see if the program im…

This study aimed to see if a 12-week supervised exercise program could improve quality of life and physical fitness in men with advanced prostate cancer receiving hormone therapy. Participants would have been randomly assigned to either the supervised program or usual care with e…

This study tests a 3-month strength training program designed for Hispanic prostate cancer survivors and their caregivers. Participants exercise together in remote group classes to improve physical and mental health. The goal is to see if the program is practical and helpful for …

This study looks at whether giving men a deeper level of muscle relaxation during robotic prostate surgery can lower the pressure used during the operation and reduce pain afterward. About 139 men having this surgery will be randomly assigned to either deep or moderate muscle rel…

This study tests whether giving magnesium sulfate during prostate surgery can lower pain and reduce the need for strong painkillers. About 68 adults having robotic prostate surgery will either receive magnesium or not, as part of their standard anesthesia. Researchers will compar…

This study tests whether a special cooling mat can reduce hot flashes and night sweats in people taking hormone therapy for breast or prostate cancer. About 40 participants will use the mat for 8 weeks and track their symptoms. The goal is to see if this simple, non-drug approach…

This study planned to compare two types of pelvic floor rehabilitation for men who still have urinary incontinence more than a year after prostate removal. One method uses standard Kegel exercises, while the other focuses on whole-body postural control. The goal was to see which …

This study tests whether placing a Urolift device in the prostate before stereotactic body radiation therapy (SBRT) can reduce urinary side effects like frequent urination, pain, and nighttime trips to the bathroom. About 20 men with both prostate cancer and benign prostatic hype…

This study tests whether eating only within a 10-hour window each day can help prevent frailty in people over 55 who are on hormone therapy for prostate cancer. Frailty makes it harder to recover from stress and can lead to loss of independence. The trial will enroll 30 participa…

This study tests whether a gentle electrical current applied to specific points on the skin (AcuTENS) can reduce pain and anxiety during a prostate biopsy. About 53 men having their first biopsy will receive either active AcuTENS or a placebo device, on top of standard numbing me…

This study looks at whether adding tramadol or magnesium to a standard local anesthetic (ropivacaine) for a nerve block can better control pain during and after robotic prostate removal. Ninety men aged 40-80 will be randomly assigned to receive one of three solutions: ropivacain…

This trial tests a new surgical method called NeuroSAFE, which uses real-time tissue analysis during robotic prostate removal to help surgeons avoid damaging nerves that control erections and bladder function. About 407 men with prostate cancer will be randomly assigned to receiv…

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

This study looks at whether men with intermediate-risk prostate cancer can follow a Mediterranean diet before their surgery to remove the prostate. The goal is to see if this diet is practical and well-tolerated. Twelve participants will eat specially prepared meals and then unde…

This pilot study aims to see if a brief educational session can increase the number of Black men with aggressive prostate cancer who complete genetic testing. Researchers will enroll 50 men who identify as Black or multiracial and have high-risk prostate cancer. Participants will…

Researchers are studying whether a mobile health app called myAria helps adult prostate cancer patients track symptoms, share health data, and feel more empowered during treatment. Participants use the app to log side effects and well-being, complete questionnaires, and view a no…

This study looks back at the records of 625 men who had robotic prostate surgery for localized prostate cancer. It compares a newer single-port method with the standard multi-port approach to see which leads to fewer complications and better urinary control. The goal is to gather…

This study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…

This study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…

This study looks at whether combining a genetic test called the Genomic Prostate Score (GPS) with MRI scans can help doctors better choose men with prostate cancer for focal therapy, which treats only the cancerous part of the prostate. Researchers will analyze data and tissue sa…

Researchers are examining whether the Gleason score, prostate-specific antigen (PSA) level, and clinical stage can predict treatment failure, death, and quality of life in men who received radiation therapy for localized prostate cancer. The study reviews medical records and ques…

This study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…

This study follows 2,500 prostate cancer survivors who had surgery at City of Hope. Researchers track their quality of life, side effects, and long-term health for years after treatment. The goal is to learn what survivors experience over time and find ways to improve their care.

This study tests whether a special PET scan, done before prostate removal surgery, can predict if prostate cancer will come back. About 175 men with high-risk prostate cancer will get the scan, then have surgery, and be followed for up to 5 years. The goal is to see if this scan …

This study is testing whether a special type of MRI scan can show early signs that high-risk prostate cancer is responding to treatment. About 32 men will get the scan before and during therapy, and results will be compared to standard tissue exams after surgery. The goal is to f…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study compares two imaging methods—micro-ultrasound and MRI—for monitoring prostate cancer in men on active surveillance. Researchers will perform biopsies guided by each technique to see which better detects cancer progression. The goal is to determine if micro-ultrasound c…

This study aims to map the genetic makeup of breast and prostate cancers in patients treated through Brazil's public health system. Researchers will analyze tumor and normal DNA from 882 participants to build a national database. The goal is to better understand how genetics and …

This study follows 200 African American prostate cancer survivors and their partners to understand how daily stress, social support, and lifestyle choices like physical activity and diet affect each other. Participants wear an activity tracker and answer surveys on their smartpho…

This registry study is collecting blood samples and health data from 1,000 people being evaluated for prostate cancer. The goal is to test the accuracy of a new blood-based test called PROSTest, which looks for genetic signals of prostate cancer activity. Researchers hope this te…

This study investigates whether genetic markers found in prostate fluid and urine can help predict if prostate cancer will come back after surgery. Researchers will analyze DNA, RNA, and gene expression in samples collected from men undergoing prostate removal. The goal is to dev…

This study looks at whether giving men with low-risk prostate cancer two extra tests—a genomic test (GPS) and a special MRI—helps them stick with active surveillance (monitoring instead of immediate treatment). Researchers will track 222 men for 18 months to see if these tests im…

This study aims to collect and analyze genetic and clinical information from up to one million people with prostate, bladder, or kidney cancer. The goal is to better understand tumor biology and how this information can be used to improve treatment decisions and outcomes. Partici…

This study looks for genetic changes that raise the risk of prostate cancer, especially in men diagnosed young or with a family history. Over 23,800 men with prostate cancer provided DNA samples. The goal is to find inherited genes linked to the disease, which could improve risk …

This study looks at how safe and doable different amounts of aerobic exercise are for people about to have surgery for solid tumors like breast, endometrial, or prostate cancer. About 60 participants will exercise at home while using apps and devices to track their activity. The …

This study looks at how the brain and pelvic floor muscles work together in men who have had or are having robot-assisted prostate surgery for prostate cancer. By recording brain activity (EEG) and muscle activity (EMG) during urination and Kegel exercises, researchers hope to id…

This study looked at whether regular screening tests for prostate, lung, colorectal, and ovarian cancers can help find cancer early and reduce deaths. Over 76,000 men and women took part, with some getting screened and others receiving usual care. The main goal was to see if scre…

This study tests whether low-intensity electrical stimulation of nerves near the prostate can help surgeons monitor and preserve erectile function during robot-assisted prostate removal. Twenty men with localized prostate cancer and normal erectile function will receive the stimu…

This trial tests whether an artificial intelligence program can automate two key steps in radiotherapy planning: outlining areas at risk of tumor spread or radiation damage, and designing the radiation beams. The AI tool is compared against the standard manual process done by onc…

This study looks at inherited gene changes (like BRCA) in men with prostate cancer to understand how common they are and how they affect treatment. Researchers will collect saliva samples and health information from 1,360 men in Washington state. The goal is to improve cancer car…

This study looks at tissue and blood samples from men with and without prostate cancer to find genetic changes linked to the disease. Researchers hope to learn what causes prostate cancer at the molecular level. The goal is to use this knowledge to develop better screening tests …

This study looks at men who had their prostate removed for cancer at least one year ago. Researchers want to understand how common and severe problems like urine leakage and erectile dysfunction are, and how these issues affect quality of life, self-esteem, and relationships. Par…

This study follows people who have received photodynamic therapy (PDT) for various cancers, including head and neck, lung, and skin tumors. PDT uses a light-sensitive drug and a special light to destroy cancer cells while sparing healthy tissue. Researchers will review medical re…

This study explores whether a genetic test can identify prostate cancer patients at higher risk for urinary side effects from radiation therapy. Researchers will track side effects in 208 men with early-stage prostate cancer who receive stereotactic radiation. The goal is to see …

This study looks at how men with low-risk prostate cancer and their partners or close allies decide on treatment. Researchers want to understand how anxiety and uncertainty influence these choices. About 541 participants will fill out questionnaires about their feelings and prefe…

This study is not testing a new treatment. Instead, it observes how 400 men with advanced prostate cancer are actually treated in Russia, and looks for biomarkers in their tumor samples. The goal is to understand current practices and identify factors that might influence outcome…

This study looks at prostate cancer tissue from men undergoing prostate removal surgery to find cells that may be especially aggressive and resistant to treatment. Researchers give a special dye (pimonidazole) before surgery to mark oxygen-starved areas, then analyze the removed …

This study tests a new type of MRI that uses a special substance (hyperpolarized pyruvate) to see how active prostate cancer tumors are. Researchers want to know if this scan can find aggressive cancers and show if treatments are working or stopping sooner than standard scans. Ab…

This study is testing whether artificial intelligence can predict if prostate cancer has spread to lymph nodes or other parts of the body by analyzing biopsy tissue images. Researchers will use samples from 3,000 men to develop and validate the AI model. The goal is to help docto…

This study is developing an artificial intelligence model to predict which patients with advanced prostate cancer are at higher risk of developing a more severe form called castration-resistant prostate cancer. The AI will analyze MRI images, biopsy slides, and clinical data from…

This study tests new ways to help rural primary care clinics provide better follow-up care for cancer survivors. Researchers will give clinics telementoring, quality improvement coaching, and an obesity management toolkit. The goal is to see if these tools help clinics follow nat…

This study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…

This study follows 214 men treated for prostate cancer to see how many develop lower limb lymphedema (leg swelling) and who is most at risk. Participants attend check-ups every three months for 18 months. The goal is to better understand this side effect and its impact on quality…

This study examines 15 proteins on prostate cancer cells from 1,600 patients to see which ones are common and whether they relate to survival. Researchers will analyze stored tissue samples and collect new ones from men with advanced cancer. The goal is to understand these protei…

This study looks at how genetic differences (SNPs) in prostate cancer patients affect their response and side effects to the drug abiraterone. Researchers will analyze DNA from 600 patients taking abiraterone plus prednisone and bicalutamide. The goal is to find genetic markers t…

This study tests whether a program that educates and supports doctors can help them follow national guidelines for prostate cancer imaging. About 58 VA doctors and staff took part. The goal is to reduce inappropriate scans for low-risk patients and ensure appropriate scans for hi…

This study tests a new way of organizing care for people aged 70 and older who have cancer (breast, lung, colorectal, or prostate) plus at least one other serious health condition. The GERONTE program brings all their doctors and nurses together using a shared digital care plan. …

This pilot study looks at whether special scans (PSMA PET/MRI) and genetic tests can predict how well high-risk prostate cancer responds to hormone therapy and radiation. Thirty participants will be followed for up to 5 years. The goal is to find markers that identify poor respon…

This study tests whether artificial intelligence can help doctors outline the prostate on ultrasound images for a type of radiation treatment called brachytherapy. Thirty-six adults with prostate cancer will have their treatment plans made both with and without AI assistance. The…

This study looks at how a new, more sensitive type of PET scan (PSMA PET) affects the anxiety, decision-making, and quality of life of 350 men with prostate cancer. Participants will fill out surveys about their feelings and experiences over a year. The goal is to understand the …

This study involves 400 men with high-risk prostate cancer who have not yet received treatment. Researchers are using a special type of scan called PSMA PET to see if it can find cancer that has spread to lymph nodes or other parts of the body, which standard scans often miss. Th…

This study tests a small implantable device that is placed inside prostate tumors to see how they respond to different cancer drugs. About 35 men scheduled for prostate removal surgery will receive the device before their operation. The goal is to learn whether this approach is s…

This study aimed to see if a specially designed website could help men with low-risk prostate cancer understand their treatment options and feel more confident in their choices. The researchers planned to enroll patients and measure their knowledge and decision-making satisfactio…

This observational registry will follow 500 men with metastatic castration-resistant prostate cancer who are receiving PSMA theranostics (177Lu-PSMA) as part of their standard care. Researchers will track how well the treatment lowers PSA levels and monitor any serious side effec…

This study compares infection rates in 300 men undergoing transperineal prostate biopsy, half receiving antibiotics and half not. The goal is to see if omitting antibiotics is safe. If proven, it could reduce unnecessary antibiotic use and side effects.

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…

This study, called PARADIGM, is not testing a new drug. Instead, it looks at whether analyzing DNA from a blood sample can tell doctors which standard treatment—like hormone therapy or chemotherapy—will work best for a patient with metastatic prostate cancer. Researchers will tak…

This pilot study tests a new MRI technique that uses a special form of bicarbonate to measure how acidic prostate tumors are. Ten men with localized prostate cancer will receive an injection of hyperpolarized bicarbonate before an MRI scan. The goal is to see if this method is sa…

This study looks at whether hormone therapy (like Lupron or Casodex) changes thinking abilities in men aged 65 and older with prostate cancer. Researchers will compare cognitive function over time between men starting hormone therapy, those who have never had it, and those who ha…

This study looks at whether a 12-week survivorship program for men with advanced prostate, kidney, bladder, testicular, or penile cancer can be successfully added to their regular follow-up care. Researchers will measure how feasible and acceptable the program is using questionna…

This study follows 120 men who had robot-assisted surgery for prostate cancer to see how they are doing 10 years later. Researchers will check if the cancer has come back, how common incontinence and erectile dysfunction are, and how satisfied patients feel. The goal is to unders…

This study looks at whether a special PET scan called Posluma can help doctors plan radiation therapy more precisely for prostate cancer. About 20 patients will get both a standard PET scan and an extra scan on the RefleXion X1 machine. The goal is to see if the new scan finds th…

This study examines DNA from over 21,000 cancer patients in New York to find gene changes linked to several cancers, including breast, colon, and lung. Researchers will compare these genes to those from healthy people to spot differences. The goal is to generate ideas for future …

This study follows 304 men in Martinique diagnosed with prostate cancer from 2020 onward. Researchers use digital questionnaires to track changes in quality of life, especially sexual and urinary issues. The goal is to gather data to improve care and reduce health gaps in the Car…

This study looks at how hormone therapy (anti-androgen treatment) for prostate cancer affects the heart. Researchers will use heart MRI scans before and after 4-7 months of treatment in 23 men. The goal is to understand changes in heart function, not to treat the cancer itself.

This study follows 200 men with prostate cancer who are receiving hormone therapy (androgen deprivation therapy) for at least 6 months. Researchers want to understand how this treatment affects the heart over time, and how factors like medical history, race, income, and access to…

This study looks at whether detailed analysis of MRI scans (called radiomics) can better predict how aggressive a prostate cancer is and whether it will come back soon after surgery. Researchers will study 125 men with prostate cancer who have an MRI before treatment. The goal is…

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study follows 490 men with low-risk prostate cancer in Brazil to see how well active surveillance works. Active surveillance means closely monitoring the cancer instead of treating it right away. The goal is to learn how often the cancer changes and how many men avoid treatm…

This study looks at how often prostate cancer survivors experience faecal incontinence (loss of bowel control) after a specific type of radiation therapy. Researchers will track 200 survivors and measure the radiation dose received by the anal sphincter to see if higher doses lea…

This study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is pu…

This study collects tissue, blood, and other fluid samples from men with prostate conditions, including those with no cancer, localized disease, or advanced stages. Researchers will analyze genetic changes and protein markers to understand why some men get prostate cancer, why so…

This pilot study tests whether a smartphone app called Prostate Cancer Genius can help African American men learn about prostate cancer and complete a home-based PSA test. Eighty men aged 55 to 69 from Oklahoma who haven't had a PSA test in two years will use either the new app o…

This study follows 250 men with prostate cancer who are receiving radiotherapy. Researchers want to see if a person's 'sense of coherence' — their ability to cope with stress — is linked to their quality of life and how they rate their own health. Participants fill out questionna…

This study looks at whether the Decipher test, which predicts how aggressive prostate cancer is, works the same for African-American men as for other men. The test was developed mainly from samples of European men, but African-American men have higher rates of prostate cancer and…

This study aimed to collect prostate tissue samples from men undergoing brachytherapy for prostate cancer. The goal was to build a biobank for research into how the cancer responds to radiation. No participants were enrolled, and the study was withdrawn before it began.

This study was designed to see how much information people with breast or prostate cancer can recall about their screening and diagnosis. Researchers planned to give participants access to their online medical records and then test if that helped them remember more accurately. Ho…

This study looks at how certain hormone therapies for advanced prostate cancer might affect memory, thinking, and brain structure. Researchers will use brain scans and thinking tests in 100 men to track changes over time. The goal is to understand which patients are more likely t…

This study was designed to test whether using smaller or larger stitches during robotic prostate surgery helps men regain bladder control faster. It planned to enroll men with prostate cancer undergoing robotic prostate removal. However, the trial was withdrawn before any partici…

This study looks at how certain hormone therapies for prostate cancer affect the heart. It compares two drugs, leuprolide and relugolix, given alongside radiation. The goal is to understand why some men develop heart problems and find ways to predict and reduce that risk. About 9…

This study looks at whether standard hormone therapy (apalutamide, darolutamide, or enzalutamide) can increase the visibility of prostate cancer cells on PSMA PET/CT scans. About 9 men with recurrent prostate cancer will take the hormone pill for a few weeks and then get a scan. …

This study looks at new ways to predict how prostate cancer and nearby healthy tissues react to a precise type of radiation therapy called SBRT. Researchers will analyze breath samples, blood DNA, and CT scans from 60 men with low- or intermediate-risk prostate cancer. The goal i…

This study tests a method called KIM that tracks the prostate's position during radiation using implanted gold markers. If the prostate moves more than 3mm, the radiation beam stops and is repositioned. The goal is to see if this technique is feasible in 100 men receiving radiati…

This study aims to find better ways to detect prostate cancer by looking at blood samples. Researchers will test special antibodies to see if they can identify cancer markers in circulating tumor cells. The study includes 40 men with prostate cancer and 20 healthy donors. It is a…

This study follows over 96,000 Seventh-day Adventists in the U.S. and Canada to see how diet and lifestyle choices relate to breast, colorectal, and prostate cancer. Researchers are focusing on intakes of meat, soy, and dairy. Because it is observational, it can show patterns but…

This observational study looks at why hormone therapy eventually stops working in advanced prostate cancer. Researchers will take tumor samples from 30 patients before and during treatment to study changes in immune cells and cancer markers. The goal is to find early signs of res…

This study looks at how screening for social needs (like food, housing, and transportation) and connecting Black breast and prostate cancer survivors with community health workers can improve their quality of life and well-being. Researchers are also testing anti-racism training …

This study looks at whether removing lymph nodes during prostate cancer surgery helps prevent the cancer from coming back in men with intermediate-risk prostate cancer. Currently, the procedure is standard but can cause side effects like swelling, blood clots, or nerve injury. Th…

This study collects blood and saliva samples from people with cancer and their relatives to build a DNA bank. Researchers hope to better understand how cancer runs in families. About 992 participants are expected to join. The samples will be stored and analyzed later for genetic …

This study looks at whether a protein in the blood called chromogranin A (CgA) can help predict if prostate cancer will come back after radiation therapy. Researchers will measure CgA levels in 118 men before, during, and after treatment. The goal is to see if changes in CgA are …

This study is looking at how things like diet, physical activity, and other lifestyle habits might affect a man's risk of getting prostate cancer. Researchers are studying more than 2000 men who are at higher risk to find biological markers in the blood that could help predict ri…

This study aims to see how prostate tumors change on MRI scans shortly after a precise type of radiation therapy (SBRT). Researchers will compare these MRI changes with PSA levels in the blood. The study involves 28 men with localized prostate cancer and is designed to improve un…

This study follows nearly 2,000 men with newly diagnosed prostate cancer to see if certain genes increase the risk of the cancer spreading. Researchers will analyze genetic markers to better predict who might face more aggressive disease. The goal is to improve early detection of…

This study looks at how two types of prostate cancer surgery affect breathing. Sixty men will be randomly assigned to either robot-assisted or open surgery. The main goal is to measure changes in peak expiratory flow (how fast you can blow air out) right after surgery and again a…

This study explores whether advanced MRI scans can detect early changes in prostate tumors and nearby healthy tissues during radiation therapy. By spotting these changes sooner, doctors might adjust treatment to improve effectiveness and reduce side effects. The study involves 38…

This study analyzes medical records and biopsy samples from 3,350 men diagnosed with localized prostate cancer between 1990 and 2006. The goal is to identify biological, pathological, and clinical markers that can predict how the disease will progress. By understanding these fact…

This study looks at whether a special type of MRI, called RSI-MRI, can predict how well prostate cancer responds to radiation and hormone therapy. About 100 men with high-risk, localized prostate cancer will get this MRI before and during treatment. The goal is to see if the scan…

This study looks at whether a 2-minute animated video can help men with early-stage prostate cancer better understand their treatment options. About 400 men will watch the video and then choose between active surveillance, focal therapy, or standard treatments. Researchers will t…

This study was designed to see if a person's race or ethnicity changes how well a combination of drugs (niraparib, abiraterone acetate, and prednisone) works for a specific type of advanced prostate cancer. It planned to compare Black or Hispanic participants with White or Native…

This study looks at whether a simple genetic test can identify men who are more likely to have prostate cancer, so screening can be focused on them. About 300 Caucasian men aged 55 to 69 will provide a DNA sample and, if their genetic risk score is high, they will be offered a pr…

The IMPACT Study is testing two online tools—GeneSHARE and LivingLabReport—to help people with inherited cancer gene variants share their results with family members and follow cancer screening guidelines. The study involves 720 adults who have a genetic variant linked to cancers…

This study was designed to observe changes in certain immune system proteins (chemokines) in the blood and urine of men with prostate cancer over time. Researchers planned to collect samples from patients starting new treatments, but the study was withdrawn before any participant…